Printer Friendly

SYNERGEN AND SELECTIDE ANNOUNCE COLLABORATION

 BOULDER, Colo./TUCSON, Ariz., Jan. 12 /PRNewswire/ -- Synergen Inc. (NASDAQ: SYGN) and Selectide Corp. announced today the signing of an agreement to jointly develop small molecule inhibitors of interleukin-1 (IL-1) and tumor necrosis factor (TNF). IL-1 and TNF are cytokines, protein molecules believed to be involved in a number of inflammatory diseases including rheumatoid arthritis, inflammatory bowel disease, asthma and multiple sclerosis.
 Under the terms of the agreement, Synergen has made a $3 million equity investment in Selectide. Selectide will also receive research funding, benchmark payments on the achievement of certain milestones and royalty payments on the sale of products that may result from the collaboration. Synergen will have exclusive worldwide marketing rights to all compounds resulting from the collaboration.
 Selectide is contributing its proprietary drug discovery technology to the collaboration, while Synergen brings its preclinical and clinical experience with cytokine inhibitors including TNF binding proteins and ANTRIL(TM), the company's IL-1 receptor antagonist (IL-1ra), now in clinical trials for a number of indications including sepsis syndrome.
 The Selectide Process is Selectide's technique for the rapid generation and screening of massive libraries of peptides and peptide- like compounds. Active molecules discovered with the Selectide Process then become the basis for further optimization through the synthesis and screening of specialized libraries, as well as traditional medicinal chemistry techniques.
 The goal of the collaboration is to discover and optimize for clinical development orally active inhibitors of IL-1 and TNF. Synergen will be responsible for preclinical and clinical development of the compounds, as well as manufacturing and marketing of the resulting products, which may be useful in the treatment of chronic inflammatory disorders. Recombinant proteins (such as IL-1ra) and monoclonal antibodies, which exhibit inhibitory activity against cytokine hormones, are currently in clinical development. However, these compounds are not orally available.
 "Selectide is pleased to be working with the leader in the field of cytokine inhibition," said Dave Madden, president and chief executive officer
of Selectide. "We believe that in teaming up with Synergen, we have the best opportunity to discover and develop promising orally active compounds."
 "In our view, Selectide has one of the most promising small molecule drug discovery technologies, as well as a top notch scientific team to produce results," added Jon Saxe, president and chief executive officer of Synergen.
 Selectide is a development stage pharmaceutical company engaged in the discovery and development of novel peptide-based drugs for the treatment of inflammatory and cardiovascular diseases and cancer. Employing the Selectide Process, a proprietary technique for the rapid synthesis and screening of large libraries of compounds, the company expects to significantly speed and improve the drug discovery process.
 Synergen is a biopharmaceutical company engaged in the discovery, development and manufacture of protein-based pharmaceuticals. The company's research is targeted toward products for inflammatory diseases, tissue repair and neurological diseases. The company is headquartered in Boulder with manufacturing operations in Boulder and Delaware, and business operations in The Hague and Kobe, Japan.
 -0- 1/12/93
 /CONTACT: Paul Laland (Media), 303-541-1325, or Debra Bannister (Financial), 303-938-6242, both of Synergen; or Dave Madden of Selectide, 602-575-8040/
 (SYGN)


CO: Synergen Inc.; Selectide Corp. ST: Colorado, Arizona IN: MTC SU:

BB -- DV003 -- 3827 01/12/93 08:16 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jan 12, 1993
Words:532
Previous Article:U.S. CUSTOMS SERVICE AUCTIONS: GOING ONE, TWICE, SOLD!
Next Article:AAA PREPARES TRIPTIK ROUTING FOR INAUGURAL BUS JOURNEY
Topics:


Related Articles
PHLX TO BEGIN TRADING LEAPS(TM) ON SYNERGEN
SYNERGEN ANNOUNCES NEW OFFICER AND MANAGEMENT APPOINTMENTS
SYNERGEN DEDICATES NEW COMMERCIAL-SCALE MANUFACTURING PLANT
AGOURON ANNOUNCES $1.8 MILLION NIH GRANT FOR NEW ANTI-HIV COLLABORATION
SYNERGEN COMPLETES PHASE III CLINICAL TRIAL ENROLLMENT FOR ANTRIL IN SEPSIS; 900 PATIENTS RECRUITED IN THE U.S., CANADA AND EUROPE
SYNERGEN BEGINS OPERATIONS IN JAPAN
PHLX LISTS ADDITIONAL STRIKE PRICES FOR SYNERGEN INC. OPTIONS
MARION MERRELL DOW INC. TO ACQUIRE SELECTIDE CORP. FOR ENABLING TECHNOLOGIES IN R&D
MARION MERRELL DOW INC. COMPLETES ACQUISITION OF SELECTIDE CORP. TO ACCELERATE DRUG DISCOVERY
HOUGHTEN NAMES LEBL AND KRCHNAK RESEARCH DIRECTORS; ADDITION OF SCIENTISTS BROADENS COMBINATORIAL CHEMISTRY EXPERTISE

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters